BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $15.50.

A number of research analysts recently weighed in on BCRX shares. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp boosted its position in shares of BioCryst Pharmaceuticals by 190.7% during the fourth quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 55,535 shares during the period. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in BioCryst Pharmaceuticals by 3.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock valued at $3,016,000 after acquiring an additional 11,581 shares during the last quarter. Woodline Partners LP bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at $3,385,000. Finally, Two Sigma Advisers LP increased its stake in BioCryst Pharmaceuticals by 14.6% in the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock worth $18,799,000 after purchasing an additional 318,800 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $9.21 on Monday. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $9.50. The business has a 50 day simple moving average of $8.01 and a two-hundred day simple moving average of $7.84. The stock has a market capitalization of $1.91 billion, a PE ratio of -15.10 and a beta of 1.75.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.